Akeso, Inc.

Detailed Description

Akeso, Inc., a clinical-stage biopharmaceutical company, engages in research, development, discovery, manufacture, and commercialization of therapies. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody for the treatment of cervical cancer, nasopharyngeal cancer, gastric cancer, gastroesophageal junction adenocarcinoma, hepatocellular carcinoma, non-small cell lung cancer, and solid tumors; and Penpulimab AK105, a PD-1 monoclonal antibody for treating non-small cell lung cancer, classic Hodgkin's lymphoma, nasopharyngeal cancer, hepatocellular carcinoma, gastric cancer, mismatch repair deficient solid tumor, small cell lung cancer, head and neck cancer, thyroid cancer, mesothelioma and thymic cancer, esophageal squamous cell carcinoma, urothelial carcinoma, gastroesophageal junction, cholangiocarcinoma, and neuroendocrine tumor. It is also developing AK119, a CD73 monoclonal antibody for the treatment of COVID-19 and solid tumors; AK109, a VEGFR-2 monoclonal antibody for treating solid tumors and gastric cancer; AK117, a CD47 monoclonal antibody for the treatment of solid tumors/lymphoma, myelodysplastic syndrome, and acute myeloid leukemia; and AK112, a PD-1/VEGF bi-specific antibody for the treatment of solid and gynecological tumors, non-small cell lung cancer, and small cell lung cancer. In addition, the company develops Ebronucimab (AK102), a PCSK9 monoclonal antibody for the treatment of hypercholesterolemia; AK120, an IL-4R monoclonal antibody for treating moderate-to-severe atopic dermatitis and asthma, and eosinophilic esophagitis; AK101, a IL-12/IL-23 monoclonal antibody for the treatment of moderate-to-severe psoriasis and ulcerative colitis; and AK111, a IL-17 monoclonal antibody for treating moderate-to-severe psoriasis and ankylosing spondylitis. The company has collaboration agreements with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Akeso, Inc. was founded in 2012 and is headquartered in Zhongshan, the People's Republic of China.

Financials